RNS Number : 0074B
Thalia Therapeutics PLC
20 April 2026

20 April 2026

Thalia Therapeutics plc

("Thalia" or the "Company")

Change of Registered Address

Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H 6DU with immediate effect.

- Ends -

For more information please contact:

Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer — Via Thalia Investor Hub
https://investors.thaliatx.com/link/y5RKGe

SP Angel Corporate Finance LLP — Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall

Northstar Communications Limited — Tel: +44 (0)20 7183 2463
Investor Relations
Sarah Hollins

About Thalia Therapeutics plc

Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.

RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.

Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to enable oral delivery, avoidance of unwanted immune responses, and excellent stability and storage.

For further information visit www.thaliatx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CROKZGMDVNZGVZM